CSBR Logo

Champions Oncology, Inc. (CSBR) 

NASDAQ
Market Cap
$61.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
272 of 971
Rank in Industry
164 of 557

Largest Insider Buys in Sector

CSBR Stock Price History Chart

CSBR Stock Performance

About Champions Oncology, Inc.

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Insider Activity of Champions Oncology, Inc.

Over the last 12 months, insiders at Champions Oncology, Inc. have bought $142,144 and sold $0 worth of Champions Oncology, Inc. stock.

On average, over the past 5 years, insiders at Champions Oncology, Inc. have bought $166,483 and sold $2.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Mendelson Daniel Newman (director) — $142,144.

The last purchase of 1,000 shares for transaction amount of $6,500 was made by Mendelson Daniel Newman (director) on 2024‑01‑12.

List of Insider Buy and Sell Transactions, Champions Oncology, Inc.

2024-01-12Purchasedirector
1,000
0.0071%
$6.50$6,500-27.48%
2024-01-11Purchasedirector
2,000
0.0147%
$6.27$12,540-22.45%
2024-01-10Purchasedirector
2,944
0.022%
$6.31$18,577-21.77%
2024-01-09Purchasedirector
3,000
0.0221%
$6.25$18,750-21.96%
2024-01-08Purchasedirector
1,000
0.0074%
$6.15$6,150-21.34%
2024-01-05Purchasedirector
2,000
0.0146%
$6.09$12,180-20.26%
2024-01-04Purchasedirector
3,000
0.0221%
$6.12$18,360-19.84%
2024-01-03Purchasedirector
500
0.0035%
$5.83$2,915-20.28%
2023-12-21Purchasedirector
2,500
0.0184%
$4.92$12,300-0.20%
2023-12-20Purchasedirector
2,100
0.015%
$4.82$10,122-1.11%
2023-12-19Purchasedirector
5,000
0.0384%
$4.75$23,750+4.46%
2023-10-11Purchasedirector
5,000
0.0385%
$6.40$32,000-18.15%
2023-10-10Purchasedirector
1,100
0.008%
$6.41$7,051-20.97%
2023-10-06Purchasedirector
1,530
0.0114%
$6.48$9,914-21.47%
2023-10-05Purchasedirector
2,000
0.0156%
$6.47$12,940-18.23%
2023-10-04Purchasedirector
5,000
0.0386%
$6.40$32,000-19.52%
2023-10-03Purchasedirector
2,500
0.019%
$6.30$15,750-19.27%
2023-09-29Purchasedirector
4,000
0.0294%
$6.16$24,640-17.71%
2023-09-28Purchasedirector
5,000
0.0379%
$6.22$31,100-15.63%
2023-09-27Purchasedirector
1,500
0.0115%
$5.95$8,925-11.16%

Insider Historical Profitability

76.5%
Mendelson Daniel Newmandirector
198625
1.4611%
$4.52302+54.24%
BROWN MICHAEL MAURICE10 percent owner
22281040
163.9059%
$4.5220
Battery Ventures IX, L.P.10 percent owner
22281040
163.9059%
$4.5220
Martell Jamesdirector
2051828
15.0939%
$4.5207
New Enterprise Associates 14, L.P.10 percent owner
1713720
12.6066%
$4.5201
ACKERMAN JOELdirector
1021731
7.5162%
$4.52101+66.02%
Morris RonnieCEO
858878
6.3182%
$4.52161+86.37%
BURKETT DOUGLAS DPresident
850
0.0063%
$4.5230
Breitfeld Philip P.director
0
0%
$4.5201

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Battery Management Corp$11.87M17.822.42M0%+$02.62
Nea Management Company Llc$8.4M12.611.71M0%+$00.04
Tocqueville Asset Management$3.35M5.04684,628+<0.01%+$245.000.05
Renaissance Technologies$611,000.000.92124,691-0.08%-$490.01<0.01
BlackRock$566,847.000.85115,683-0.36%-$2,028.60<0.0001
The Vanguard Group$419,460.000.6385,604+3.34%+$13,558.31<0.0001
ESSEX INVESTMENT MANAGEMENT CO LLC$378,280.000.5777,2000%+$00.08
Goldman Sachs$339,575.000.5169,301New+$339,575.00<0.0001
Geode Capital Management$304,433.000.4662,114+1.25%+$3,749.42<0.0001
Northern Trust$209,176.000.3142,689-4.96%-$10,917.19<0.0001
Morgan Stanley$199,430.000.340,700+347.25%+$154,840.00<0.0001
Hightower Advisors$168,000.000.2534,308+9.83%+$15,033.23<0.0001
Acadian Asset Management$148,000.000.2330,6970%+$0<0.01
BNY Mellon$131,070.000.226,749-13.08%-$19,727.38<0.0001
State Street$130,110.000.226,5530%+$0<0.0001
Bank of America$126,547.000.1925,826-0.01%-$19.60<0.0001
Citadel Advisors LLC$62,843.000.0912,825-12.32%-$8,829.87<0.0001
Mesirow Financial Investment Management Inc$60,662.000.0912,380New+$60,662.00<0.01
Cambridge Investment Research Advisors Inc$60,000.000.0912,252New+$60,000.00<0.0001
Stifel$54,841.000.0811,192New+$54,841.00<0.0001
Simplex Trading Llc$7,000.000.011,597New+$7,000.00<0.0001
UBS$5,424.000.011,107-50.34%-$5,497.50<0.0001
Royal Bank of Canada$0<0.0164-70.91%-$0<0.0001
JPMorgan Chase$54.00<0.0111-89%-$436.91<0.0001
Wells Fargo$230.00<0.0147+2.17%+$4.89<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.